Healthcare
COMPASS Pathways plc(CMPS)
Live Price
Offline$11.49
-2.54% today
1Y Change
+316.30%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $900.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -33.9%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
COMPASS Pathways plc (CMPS) is a Healthcare stock with a market cap of $900.00M and listed on NASDAQ. The stock last traded around $11.49 and up 316.3% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -33.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -33.9%, free cash flow -31.9% with operating margin 0.0% and ROIC 996.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CMPS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -33.9%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -2.4% | +9.1% | +13.7% |
2026 Mar 24, 2026 | -43.9% | +7.7% | +5.9% | +67.6% |
2025 Nov 4, 2025 | +5.0% | -17.2% | -14.0% | -23.2% |
Benchmark Edge
CMPS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CMPS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CMPS Max Drawdown
-38.22%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CMPS and SPY.
Company Overview
COMPASS Pathways plc
NASDAQ
Compass Pathways plc Depositary Receipt represents shares in Compass Pathways plc, a biotechnology company focused on mental health innovation in the United Kingdom and the United States. The company develops COMP360, a proprietary investigational formulation of synthetic psilocybin therapy administered with psychological support, currently advancing through Phase III clinical trials for treatment-resistant depression. It is also in Phase II trials for post-traumatic stress disorder and anorexia nervosa. Compass Pathways plc pioneers a novel treatment model aimed at addressing unmet needs in mental health care for patients unresponsive to existing therapies. Its pipeline emphasizes evidence-based psychedelic-assisted therapies to improve outcomes in severe psychiatric conditions. Founded in 2020 and headquartered in London, United Kingdom, the company plays a significant role in the emerging field of psychedelic medicine development.
- Leadership
- Mr. Kabir Kumar Nath M.A., M.B.A.
- Employees
- 156
- Street Address
- 33 Broadwick Street
- Mailing
- London, W1F 0DQ
- Region
- London, United Kingdom
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- -33.9%
- Free Cash Flow
- -31.9%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -335.9%
- ROIC
- 996.5%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.77
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.